

Market Announcement

24 August 2023

BCAL Diagnostics Limited (ASX: BDX) – Trading Halt

Description

The securities of BCAL Diagnostics Limited ('BDX') will be placed in trading halt at the request of BDX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 28 August 2023 or when the announcement is released to the market.

Issued by

Lisa Banh

Senior Adviser, Listings Compliance

ASX Announcement

24 August 2023

The Manager
Issuers Department
Australian Securities Exchange

Request for a Trading Halt

BCAL Diagnostics Limited (ASX:BDX) (the Company) requests a trading halt to the trading of the Company's securities until the earlier of an announcement concerning a share placement or 28 August 2023.

In accordance with listing rule 17.1 the company advises that:

1. The trading halt is necessary as the Company is undertaking a bookbuild in relation to the share placement.
2. The Company wishes the trading halt to last until as such time it makes an announcement to the market concerning the share placement or Monday 28 August 2023, whichever is the earlier.
3. The Company is not aware of any reason why the trading halt should not be granted.

This announcement has been approved by the BCAL Board.

Yours faithfully

A handwritten signature in black ink, appearing to read "Guy Robertson".

Guy Robertson
Company Secretary

About BCAL Diagnostics

BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade BCAL has developed a non-invasive blood test for the detection of breast cancer. The test is initially designed to complement current imaging technologies, such as the mammogram, with the aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes. BCAL has partnered with Precion Inc. to optimise protocols and procedures for the clinical studies required for regulatory approvals across several jurisdictions, commercialisation and market entry points.

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/>

About Precion Inc

Precision applies mass spectrometry technology to develop and provide targeted metabolite panels for profiling various chronic disease conditions and associated health areas for clinical research. Precision offers development of diagnostics and precision medicine assay formats for downstream applications. Precision's testing services for commercial and research customers provide data for various sample types and project objectives. Precision offers a range of targeted panels and custom developed panels for partners with specific clinical objectives. For more information: <https://www.precion.com/>